From January 1, investors should expect negligible sales from Revlimid, CFO MV Narasimham tells Moneycontrol. In Q3, US revenues slipped by $35 million sequentially primarily due to lower Revlimid con ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback